SCHEMBL208324

SCHEMBL208324

N[C@H](Cc1cccnc1)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.65
ALPI P09923 1/20 0.65
PKM P14618 1/20 0.65
PTGS1 P23219 1/20 0.65
XIAP P98170 1/20 0.65
HSD17B10 Q99714 1/20 0.63
KDM4E B2RXH2 1/20 0.57
NAPRT Q6XQN6 1/20 0.56
FDPS P14324 1/20 0.54
TBXAS1 P24557 3/20 0.54
CYP1A2 P05177 2/20 0.53
RECQL P46063 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
ANPEP P15144 1/20 0.49
ERAP2 Q6P179 1/20 0.49
ERAP1 Q9NZ08 1/20 0.49
GRIA2 P42262 1/20 0.49
SLC1A5 Q15758 1/20 0.48
GRM8 O00222 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5056888 1.00 SLC7A5 (0.65) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL30655750 1.00 SLC7A5 (0.65) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL30801039 1.00 SLC7A5 (0.65) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL124364 1.00 SLC7A5 (0.65) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL124365 1.00 SLC7A5 (0.65) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL29432890 1.00 SLC7A5 (0.65) SLC7A5ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL5967081 0.98 SLC7A5 (0.62) SLC7A5ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL10957459 0.98 SLC7A5 (0.62) SLC7A5ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL20502132 0.98 SLC7A5 (0.62) SLC7A5ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL22775903 0.98 SLC7A5 (0.62) SLC7A5ALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 510 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025217074-A1 KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. (US) 2025-10-16 WO claimed
CN-120121745-A Method for detecting degarelix acetate impurity 苏州天马医药集团天吉生物制药有限公司 2025-06-10 CN claimed
WO-2025100520-A1 PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE ペプチドリーム株式会社 2025-05-15 WO claimed
WO-2025032025-A1 STABLE GLASSY MATERIAL BASED ON HISTIDINE, ARGININE AND GLUTAMIC ACID AMINO ACIDS VITROPEP (FR) 2025-02-13 WO claimed
CN-119192296-A Polypeptide compound, pharmaceutical composition and application 杭州禾泰健宇生物科技有限公司 2024-12-27 CN claimed
US-20240391954-A1 MC4R AGONIST PEPTIDES THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2024-11-28 US claimed
WO-2024210903-A1 MODIFIED PEPTIDE LIGANDS FOR STABLE DELIVERY OF HIGHLY POTENT PAYLOADS TO TUMORS: METHOD OF MAKING AND USING SAME LAMHARZI NAJIB (US) 2024-10-10 WO claimed
WO-2024211779-A1 AFFINITY PEPTIDES FOR DIAGNOSIS AND TREATMENT OF VIRAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-10-10 WO claimed
WO-2024206577-A1 KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. (US) 2024-10-03 WO claimed
EP-4392072-A1 MC4R AGONIST PEPTIDES The Regents Of The University Of Michigan (US) 2024-07-03 EP claimed
US-20240082409-A1 Modified peptide ligands for stable delivery of highly potent payloads to tumors: Method of making and using same LAMHARZI NAJIB (US) 2024-03-14 US claimed
WO-2023028538-A1 MC4R AGONIST PEPTIDES THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-03-02 WO claimed
US-20200146989-A1 A CO-AMORPHOUS FORM OF A SUBSTANCE AND A DIPEPTIDE UNIVERSITY OF COPENHAGEN (DK) 2020-05-14 US claimed
EP-3559016-A1 A CO-AMORPHOUS FORM OF A SUBSTANCE AND A DIPEPTIDE University of Copenhagen (DK) 2019-10-30 EP claimed
WO-2018113891-A1 A CO-AMORPHOUS FORM OF A SUBSTANCE AND A DIPEPTIDE UNIVERSITY OF COPENHAGEN (DK) 2018-06-28 WO claimed
CN-103145855-B Matrix metallo-proteinase inhibitor polypeptide and application thereof NANJING ANJI BIOTECHNOLOGY CO LTD 2015-04-22 CN claimed
CN-103145855-A Matrix metallo-proteinase inhibitor polypeptide and application thereof NANJING ANJI BIOTECHNOLOGY CO LTD 2013-06-12 CN claimed
EP-0192492-B1 PEPTIDES CONTAINING AN ALIPHATIC-AROMATIC KETONE SIDE CHAIN THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1992-01-02 EP claimed
US-20260124313-A1 SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN UNIV CALIFORNIA (US) 2026-05-07 US disclosed
US-4642332-A ANTIGROWTH, ANTICANCER AGENTS; PROSTATE GLANDS THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1987-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240391954-A1 MC4R AGONIST PEPTIDES MC4R, MC3R, MC5R SLC7A5 474/4885ALPI 3619/4885PKM 3504/4885
US-20260124313-A1 SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN GLP1R, ALB, GIPR SLC7A5 2195/4885ALPI 1697/4885PKM 3500/4885
US-20200146989-A1 A CO-AMORPHOUS FORM OF A SUBSTANCE AND A DIPEPTIDE DNPEP, PEPD, IDUA SLC7A5 436/4885ALPI 2744/4885PKM 3274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.